Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jazz Pharmaceuticals
Biotech
Jazz's Actio buyout gives rise to Setara with $90M series A
The spinout's lead asset targets a rare inherited neuropathy, with potential applications in the much larger overactive bladder population.
Michael Gibney
Oct 30, 2026 6:30am
After Enhertu: The slow hunt for next-gen HER2 breast cancer drugs
Oct 28, 2026 9:00am
Roche nabs expanded FDA approval for Ziihera diagnostic
Aug 27, 2026 8:00am
Jazz pays $820M to add epilepsy-focused Actio to its orchestra
Aug 10, 2026 10:40am
Jazz, AbCellera strike TCE discovery and development deal
Jun 17, 2026 7:00am
Takeda inks $1.7B AI discovery deal with Iambic Therapeutics
Feb 9, 2026 8:00am